Key Market Drivers, Trends, and Forecast for the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Valued at Present and by 2029?
In recent years, the market size for diagnostics and therapeutics of exocrine pancreatic insufficiency (epi) has expanded significantly. Its growth is projected to accelerate from $5.69 billion in 2024 to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The increase during the historic period can be credited to a larger incidence of related conditions, advancement in diagnostic instruments, progress in pharmaceuticals, and enhanced global access to healthcare.
The market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (epi) is projected to experience robust expansion in the upcoming years, with expectations to escalate to “$8.21 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.7%. The market augmentation during the forecast period is expected to be driven by factors such as telemedicine and remote monitoring, artificial intelligence and data analytics, patient enlightenment and support, regulatory amendments and revising reimbursement policies. The forecast period can also expect to see trending elements including personalized treatment techniques, the invention of innovative therapies, minimally invasive diagnostic procedures, and collaborative care structures.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
#What Drivers Are Influencing Growth In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The rise in diabetes cases is anticipated to boost the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Diabetes is a lasting metabolic disorder marked by elevated blood sugar levels (hyperglycemia) over an extended period, caused by the body failing to produce or effectively utilize insulin. EPI treatment, encompassing pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption for individuals with diabetes and EPI, as well as better glycemic control. For example, the UK’s National Health Service (NHS England) reported in June 2024 that the count of individuals recognized as pre-diabetic rose to 3,615,330 in 2023, an 18% growth from 3,065,825 in 2022. Moreover, among those below 40, there was a nearly 25% increase in cases, from 173,166 in 2022 to 216,440 in 2023. Hence, the growing prevalence of diabetes is fueling the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
What Long-Term Trends Are Likely To Affect The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Prominent companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry are utilizing strategic partnerships to boost technology assimilation and broaden their market influence. Such partnerships refer to a synergy between two or more entities aimed at pooling resources, skills, and efforts toward achieving shared targets or objectives. To illustrate, Codexis, Inc., a protein engineering firm based in the US, and Nestlé Health Science, a Swiss nutrition science firm, reported preliminary results in February 2023 from their Phase 1 clinical trial on CDX-7108. This product under investigation targets treatment for EPI. The outcomes of this Phase 1 trial set the stage for subsequent trials that may enhance treatment solutions for patients affected by EPI substantially.
Which Companies Play A Key Role In The Development Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
What Are The Key Regional Developments Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
